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Introduction
Limited disease small cell lung cancer (LD-SCLC) is a potentially curable disease that requires timely
coordination of efforts from multiple disciplines. The multidisciplinary team (MDT) meeting is an ideal
forum and starting point to discuss each patient in consideration of relevant information from the
perspective of all involved specialists.
Role of multidisciplinary teams
MDTs have a long and complex history; they co-developed with educational sessions, regular collaboration
among specialists and tumour boards [1, 2]. An MDT meeting is a meeting of a group of people from
different healthcare disciplines at a given time to discuss individual patients [3].
Simple organisational versions are based on a unidisciplinary team. These usually consist of the patient,
primary treating physician and one or more specialists. Decisions in these teams are often dominated by a
single individual. MDTs arise by participation of further specialists and include perspectives from the
different disciplines in the decision-making process. Ideally, a transdisciplinary team develops, as described
in the continuum model [4]. In a well-working transdisciplinary team cooperation is automatic and
barriers between disciplines are removed. Recommendations are based on interdisciplinary insights instead
of hierarchical structures. Core team members communicate closely and involve a multitude of other
agents, e.g. general practitioners, social workers, physiotherapists, administrators, clinical trial specialists
and nurses, to achieve the best possible results for the patient [1, 5, 6].
The aim of MDTs is to improve cancer care, although in lung cancer evidence demonstrating a clear survival
benefit is controversial [3, 7–9], and evidence is even scarcer for SCLC. Several trials reported outcomes
before and after the implementation of MDTs; only three of these included a small number of patients
with SCLC [10–12]. A systematic review by COORY et al. [3] identified only one randomised trial [13]
including SCLC investigating the impact of MDTs. Despite lacking evidence for SCLC, evidence from breast,
head-and-neck and rectal cancer has demonstrated that MDTs can reduce rates of positive surgical margins,
reduce costs, improve patient satisfaction, improve documentation regarding TNM (tumour, nodes,
metastasis) staging or performance status and even decrease the time from diagnosis to treatment [5, 14–17].
The time factor in particular is very important in SCLC where fast-track procedures should be considered [1].
Without treatment, patients with SCLC rarely survive longer than a few weeks to months [5]. Insufficient or
late treatments have been associated with poor outcomes [18–20].
Having multiple specialists involved early enables them to anticipate problems or address issues ahead.
PRADES et al. [9] hit the mark: “the rationale behind the more comprehensive structuring of teamwork in
cancer care goes beyond eventual clinical outcomes and embraces the process of care as a whole”. Spatial
issues should not be a limiting factor nowadays; depending on the setting, a telecommunication solution
might be implemented when physical meetings are difficult [12].
Tumour boards have now developed into multidisciplinary platforms for care teams which, ideally in
agreement, recommend further diagnosis and management, take responsibility for these recommendations,
and implement them in close partnership with the patient [21]. Tumour boards are established in most
hospitals across Europe; however, wide variations of implementation and organisational details exist [6].
These variations, or lack of implementation, are even larger across the world [22]. The European Respiratory
Society and the American Thoracic Society have declared tumour boards the standard of care [23].
Although referral practice may vary [24, 25], the basic steps shown in figure 1 are generally followed in the
typical management of SCLC.
From symptoms to diagnosis: the multidisciplinary approach
About 30% of patients will present with LD-SCLC at the time of diagnosis [26–28]. Owing to the high
proliferation rate of this tumour type, time should not be wasted. Patients often present to physicians with
various symptoms, including paraneoplastic syndromes [29]. Potentially, not every clinician will identify
all symptoms properly or be able to initiate the correct first steps; however, with proper presentation and
the expertise of an MDT, relevant problems can be identified and approached.
The goal of diagnostics is to establish the underlying disease and precisely define the tumour stage of
SCLC; this is the basis for the subsequent treatment recommendation by the MDT. Statements from the
radiation oncologist or surgeon regarding potential local treatments may impact the type of diagnostics
being performed and this also applies to information about patient preference or suitability of lesions for
potential biopsies. Multiple diagnostic modalities are available, such as multidetector computed
tomography (CT), positron emission tomography (PET)/CT, magnetic resonance imaging (MRI), PET/MRI,
endobronchial ultrasound (EBUS)-guided fine needle aspiration and bone scanning [30]. Although the
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sensitivity and specificity of imaging is improving, histopathological diagnosis is not obsolete. In an MDT
it is the task of the radiology and nuclear medicine specialists to show and interpret their results and
facilitate their correct interpretation. Conclusions are best drawn by considering all available data, and the
team requires information beyond imaging and histology, including patient information (e.g. smoking
history and geographical background) and/or clinical expertise (e.g. considerations on differential
diagnoses by the respiratory physician).
Although outdated, SCLC is still commonly staged using the Veterans Administration Lung Study Group
system [31]. LD-SCLC means that the cancer is confined to one hemi-thorax, all of which can be
encompassed in a safe radiotherapy field. The seventh edition of the Union for International Cancer
Control TNM Classification of Malignant Tumours (2009) as well as the updated eighth edition (2016)
recommend the use of the TNM classification for staging SCLC, which also has a demonstrated prognostic
value [32, 33]. LD-SCLC now corresponds to T1–4 N0–3 M0 tumours, whereas metastatic tumours
encompass former extensive disease (ED-SCLC).
Histological confirmation should always be sought in a timely fashion [34, 35]. The rate of pathological
tissue confirmation is higher among patients discussed at an MDT [24]; however, obtaining tissue samples
can be challenging and may require multiple specialities [36]. The team should ensure that the most
conveniently accessible site with the highest chance of obtaining tissue is targeted first, minimising the risk
of repetitive procedures [37]. Potential side-effects should be considered individually for each patient (e.g.
the risk of pneumothorax based on lung imaging). CT and PET/CT images can provide a valuable basis for
determining the best strategy, which may include various combinations of imaging and external biopsies
and/or transbronchial or surgical approaches, making interdisciplinary exchange essential [26, 38, 39].
Once tissue samples have been retrieved, histological evaluation can be challenging due to differential
diagnoses [26, 40–43]. Information on a history of inflammation or the presence of other malignancies
such as lymphoma is crucial to the pathologist and is essential information that must be communicated.
SCLC can present as an extensively necrotic neoplasm, making histological diagnosis difficult. Biopsies
should take details of imaging into account and provide a good opportunity to include a broad team in
the process. Depending on local practice, the pathologists may be actively involved in obtaining biopsies.
Pathologists can be pivotal in differentiating recurrence from a new primary or a metastasis from a
different neoplasm, with a major impact on treatment decisions.
Mediastinal staging is recommended before curative treatment [44]. EBUS bronchoscopy is preferred for
the staging of mediastinal lymph nodes. Mediastinoscopy can be used to sample mediastinal lymph nodes
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FIGURE 1 Basic steps in the management of small cell lung cancer (SCLC). LD: limited disease; MDT: multidisciplinary team; GP: general
practitioner; cMRI: cranial magnetic resonance imaging; PET: positron emission tomography; CRT: chemoradiotherapy; CT: computed
tomography; PCI: prophylactic cranial irradiation.
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not accessible with EBUS or with inconclusive results [45]. The pulmonologist, thoracic surgeon and
imaging specialist should all be involved in mediastinal staging.
Since in most institutions MDT meetings will occur once a week, potential delays in the management of
SCLC need to be weighed against the advantages of such meetings. The MDT should be involved
throughout the patient pathway, before and after the meeting, especially when treatment is initiated in an
acute setting. Relevant information needs to be available for the MDT and the questions to the board
should always be specific [1]; this might seem obvious, but all of the current co-authors have experienced
otherwise. The results should be well documented and communicated [20, 46].
On average, the time from the first abnormal radiological finding to the first day of treatment in all lung
cancer patients is ∼2.5 months [47, 48], which may be deleterious in this fast-growing tumour. After
therapy is proposed, initiation of radical treatment in lung cancer involving radiotherapy or surgery
usually requires 2–3 weeks [24]. In SCLC, in particular, there are some scenarios demanding rapid
introduction of therapy, such as vena cava superior syndrome or syndrome of inappropriate antidiuretic
hormone. The most intense teamwork is required in the first days when diagnosis and staging are
performed and the first treatment initiated. Treatment start within 1–2 weeks after suspected SCLC should
be pursued. This is even more important for symptomatic patients.
Breaking bad news
Receiving a diagnosis of lung cancer can be devastating, and many patients are left with feelings of
hopelessness and uncertainty about the future. Accurate and sensitively delivered information is crucial
and, next to physicians, lung cancer specialist nurses are a valuable resource in this regard. Nurses act as
key workers, offering practical and emotional support, and providing a consistent presence at clinic
appointments. This support is critical not at a single time-point, but throughout the process of diagnosis
and beyond [49]. Their role throughout the multidisciplinary process should not be underestimated.
Psycho-oncologists should also be integrated very early in the disease course, especially for teaching in
self-coping strategies, one of the key factors that enable the patient to adapt to distress, leading to a better
quality of life [50].
Coordinating treatment
Radiochemotherapy
Once the diagnosis of LD-SCLC is established the standard treatment for fit patients will be concurrent
radiochemotherapy [39], but chemotherapy is often initiated first to rapidly counter the fast-growing
tumour [35]. Chemotherapy should commence without delay after the tumour board decision. SCLC is a
chemo-sensitive tumour and a rapid response is often observed. Even in urgent situations with vena cava
superior syndrome [51] rapid initiation of chemotherapy is preferred over interventional radiological
treatment [52], yet both should be evaluated. In the meantime, preparation for radiotherapy should be
initiated [26, 39].
The current standard chemotherapy regime for ED- and LD-SCLC in the Western world consists of four
to six cycles of platinum and etoposide [26]. Combination therapies have been shown to be superior to
single-agent treatment [53, 54].
Historically, twice-daily and once-daily radiotherapy regimes have evolved for SCLC side-by-side [55–61].
SCLC can be treated with daily radiotherapy (to 66 Gy) or with twice-daily treatment (to 45 Gy), both
with a relatively favourable 3-year survival rate of ∼40% and similar toxicity rates [62]. Patient preference
should be accommodated when choosing among these regimes; the decision may be influenced by factors
such as availability of transportation.
Two meta-analyses demonstrated that concurrent radiochemotherapy improved survival [39, 63, 64]. In
addition to an absolute gain of 5% in overall survival at 5 years (23.7% versus 18.3%) with concomitant
radiochemotherapy [65], it is important to evaluate the general condition of the patient. The expected
survival benefit needs to be weighed against potential increased toxicity [59, 65]. The decision for either
should be met by an MDT considering the overall performance status, age and comorbidities of the
patient. Typically, multiple disciplines are involved during radiochemotherapy; side-effects such as
neutropenic fever, pneumonia or oesophagitis require rapid and precise communication to initiate timely
counter-measures and potentially adapt treatments, avoiding unnecessary treatment breaks. It should be
noted that age alone should not be considered a prohibiting factor to concurrent treatment [66].
Despite controversial findings in the literature [67–69], most data and guidelines support early thoracic
radiotherapy beginning with the first or second cycle when cisplatin-based chemotherapy is used [26, 39,
68, 70–72], as the majority of studies indicate a benefit with early radiotherapy [73].
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In some cases radiotherapy may be considered too toxic due to the extent of the disease and pre-treatment
assessment [38, 74]. Transdisciplinary teamwork is important between radiologists and radiation
oncologists to ensure correct volume definition. If the treatment volume remains too extensive then
delaying radiotherapy after an initial shrinking of the tumour may be a viable option.
Various factors influence treatments, including insurance status, availability of technology, professional
and patient preference, or even rural or urban location [75]. A review in the Commonwealth of Kentucky
in the USA demonstrated utilisation of radiochemotherapy in approximately two-thirds of LD-SCLC
patients [76], which corresponds to other reported utilisation rates [77, 78], despite a relatively high
proportion of rural settings. Although clear evidence is difficult to obtain, the improvements in outcome
in LD-SCLC in recent decades are being attributed to higher utilisation rates of active or multimodal
treatment [76, 79], which is at least partially facilitated by MDTs [80, 81].
Prophylactic cranial irradiation
The risk of brain metastases can be nearly halved in LD-SCLC with the use of prophylactic cranial
irradiation (PCI) [82–85]. PCI is favourable for patients with at least stable disease after
radiochemotherapy, demonstrating a significant improvement in overall survival [86]. Response evaluation
should be interdisciplinary, including the treating clinicians and imaging specialists. Close communication
is required to avoid confusing radiation-induced changes with progressive disease. Cranial MRI before PCI
should be considered as it identifies patients who might require therapeutic whole-brain radiotherapy
(with a higher dose) for brain metastases [87]. Before initiating PCI, prognostic factors such as
performance status, age, life expectancy and comorbidities need to be considered and presented in the
MDT meetings by the treating clinicians. Advanced age only should not rule out PCI [88].
The risk for neurocognitive decline after PCI has been reported as 30–60% after 1 year [85, 89–91],
depending on the measure of neurocognitive impairment. Patients at higher risk for neurocognitive
deterioration (e.g. with diabetes or pre-existing cerebrovascular problems) [92–94] should be critically
evaluated, involving neurologists for neurocognitive assessments. An important region for neurocognitive
function is located in the hippocampus and current research includes investigating hippocampal-sparing
cranial irradiation to reduce neurocognitive dysfunction [95, 96].
In addition to neurocognitive dysfunction, hair loss is another detrimental side-effect. Patients have to be
prepared for hair loss, potentially with the help of psycho-oncologists, to minimise the impact on quality
of life. When PCI is not implemented, close follow-up with cranial MRI should be performed if
therapeutic radiotherapy would be an option [97].
Lifestyle modification
Lifestyle modification can also improve outcomes. SCLC represented 17% of lung cancer cases in the USA
in 1986 and declined to 13% in 2002, likely attributed to changes in smoking behaviour [98]. Outcomes
are improved even when smoking is stopped after diagnosis [99, 100]. Multidisciplinary lung cancer
treatment programmes offer an ideal environment to optimally deliver effective smoking cessation services.
Smoking cessation should be offered utilising the services of dedicated smoking cessation programmes and
tailoring cessation interventions to the patient’s cancer treatment plan [101].
Individual treatment approaches
Surgery
Surgery can be considered for several indications in SCLC patients: in localised disease, for mixed
histological tumour types, for salvage resection for persistent local disease after radiochemotherapy and for
early locally relapsed (potentially chemo-resistant) tumours [102]. Recent analyses of the SEER
(Surveillance, Epidemiology and End Results) database (seer.cancer.gov) also, with limitations, suggest that
surgery may be appropriate for some patients with localised disease [82, 83].
Despite these uncertainties, surgery is an option for T1–2 N0 SCLC in current guidelines after appropriate
staging [26, 103]. It is important that surgical resection and its potential extent are discussed in an MDT,
bringing this option to attention.
Before radical treatment, interdisciplinary cardiopulmonary function testing of the patient should be
performed [74], including pulmonologists and nuclear medicine specialists for evaluation of lung function,
surgeons estimating the extent of surgery, and anaesthesiologists evaluating operability.
Lobectomy is favoured over segmental or wedge resections; obviously, an R0 (complete excision) needs to
be achieved [39].
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Evidence for the use of PCI after complete resection of SCLC is limited. However, PCI should be discussed
by the MDT [104].
Adjuvant treatment
After resection, further therapy has to be discussed with all involved specialists, including pathologists,
radiologists, oncologist, surgeons and radiation oncologists. With a high risk of loco-regional recurrence,
surgery alone is not sufficient [105]. Adjuvant chemotherapy is recommended even in patients with pN0
lymph node status [106, 107]. In the case of positive nodes, post-operative radiation therapy should also be
discussed [108, 109].
The decision should be made considering performance status, age, lung function, comorbidities and extent
of disease, and with close collaboration between pulmonologists, surgeons and pathologists. In case of an
inadequate resection margin (R1), the involved surgeon and the pathologist support the radiation
oncologist in defining the target if radiotherapy is indicated.
Novel treatment approaches
Whether immunotherapy improves outcomes in LD-SCLC is currently under investigation. The MDT
provides a good platform to present ongoing trials to colleagues of other disciplines and to select patients
for whom trial participation can be proposed. Patients who are seen by MDT members have a higher
enrolment rate in clinical trials [110]. The support of a study nurse cannot be underestimated, to the
patient as well as the treating physicians.
Follow-up
High recurrence rates justify follow-up. Follow-up includes contrast-enhanced CT [26, 39, 111]. The aim
of close follow-up is early detection of recurrence in a stage where patients still have a good performance
status and localised disease. Next to imaging, smoking cessation should be actively discussed. Although
plasma progastrin-releasing peptide with or without neuron-specific enolase measurements may be a
useful diagnostic marker to detect early recurrence [112–115], prospective trials evaluating the benefit are
lacking and therefore routine tumour marker assessment is not recommended in this setting.
Any form of suspected recurrence should be discussed in an interdisciplinary setting; post-radiotherapy
changes in the lung might need interpretation. Histological verification may exclude a second primary
tumour which could be treated in a potentially curative manner. Second-line treatments are at least as
multidisciplinary as the primary treatment. Referral to palliative care services among patients who were
discussed at tumour boards is higher, suggesting that symptom control and quality of life can be better
addressed in an MDT setting [7].
Follow-up also serves to detect and treat treatment-related side-effects. Depending on the setting,
follow-up is often performed by a single specialist. Feedback to the MDT and cooperation is crucial for
correct interpretation and treatment.
Summary
SCLC is a rapidly growing tumour with poor prognosis, even in LD-SCLC. Optimal treatment involves
timely concurrent radiochemotherapy and prophylactic brain irradiation in most patients. For this to be
delivered optimally, diagnosis and staging need to be well coordinated, timely and accurate. Well-organised
interdisciplinary collaboration is essential to facilitate adequate treatment considering all aspects of care,
including patient preference.
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